MAN1C1

Across TCGA pan-cancer cohorts, MAN1C1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAN1C1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAN1C1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAN1C1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where MAN1C1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.968	0.443	.006	6	view →
GBM	OS	Tertile	All	0.257	0.582	.010	5	view →
CCRCC	DFS	Median	II,III,IV	0.451	1.000	.016	3	view →
LSCC	DFS	Median	III,IV	0.903	0.601	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAN1C1–PDAC (DFS)

Open the PDAC breakdown →